Free Trial

Aardvark Therapeutics (AARD) Competitors

Aardvark Therapeutics logo
$13.82 +0.35 (+2.60%)
As of 09:44 AM Eastern

AARD vs. SYRE, ZYME, AMPH, SANA, RCUS, PROK, VERV, LENZ, BGM, and ORIC

Should you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Spyre Therapeutics (SYRE), Zymeworks (ZYME), Amphastar Pharmaceuticals (AMPH), Sana Biotechnology (SANA), Arcus Biosciences (RCUS), ProKidney (PROK), Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), BGM Group (BGM), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.

Aardvark Therapeutics vs. Its Competitors

Spyre Therapeutics (NASDAQ:SYRE) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Spyre Therapeutics presently has a consensus target price of $53.40, indicating a potential upside of 211.13%. Aardvark Therapeutics has a consensus target price of $33.00, indicating a potential upside of 138.78%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than Aardvark Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
Aardvark Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aardvark Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -77.46% -41.06%
Aardvark Therapeutics N/A N/A N/A

In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 1 articles in the media. Spyre Therapeutics' average media sentiment score of 1.87 beat Aardvark Therapeutics' score of 0.93 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Spyre Therapeutics Very Positive
Aardvark Therapeutics Positive

Aardvark Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K1,162.46-$208.02M-$3.77-4.55
Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A

Summary

Spyre Therapeutics beats Aardvark Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AARD vs. The Competition

MetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$299.89M$3.04B$5.71B$9.50B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A20.8727.8819.97
Price / SalesN/A324.50452.35101.58
Price / CashN/A43.2336.5558.97
Price / BookN/A8.328.635.89
Net Income-$20.59M-$55.19M$3.24B$258.50M
7 Day Performance18.93%5.61%3.90%2.07%
1 Month Performance-10.14%17.39%10.47%12.39%
1 Year PerformanceN/A4.47%34.29%19.25%

Aardvark Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AARD
Aardvark Therapeutics
N/A$13.82
+2.6%
$33.00
+138.8%
N/A$299.89MN/A0.0018Gap Down
SYRE
Spyre Therapeutics
2.465 of 5 stars
$16.99
+0.6%
$53.40
+214.3%
-42.7%$1.02B$890K-4.5073Positive News
ZYME
Zymeworks
2.9581 of 5 stars
$14.61
+0.9%
$21.00
+43.7%
+34.7%$1.02B$93.38M-9.74460Upcoming Earnings
AMPH
Amphastar Pharmaceuticals
4.4742 of 5 stars
$21.57
-0.6%
$32.33
+49.9%
-45.4%$1.02B$731.97M7.822,028
SANA
Sana Biotechnology
3.2063 of 5 stars
$4.52
+1.6%
$9.17
+102.8%
-16.2%$1.02BN/A-5.12380
RCUS
Arcus Biosciences
1.5778 of 5 stars
$9.56
+1.4%
$21.29
+122.8%
-32.2%$1.01B$258M-2.28500
PROK
ProKidney
3.4298 of 5 stars
$3.40
-3.5%
$6.25
+84.0%
+55.2%$988.16M$80K-5.633
VERV
Verve Therapeutics
2.9104 of 5 stars
$10.96
+0.0%
$14.57
+33.0%
+57.2%$976.53M$32.33M-5.19110News Coverage
LENZ
LENZ Therapeutics
1.3176 of 5 stars
$34.55
-0.1%
$46.60
+34.9%
+41.9%$972.58MN/A-19.52110Gap Up
BGM
BGM Group
N/A$10.01
+3.7%
N/AN/A$971.71M$25.10M0.00298
ORIC
Oric Pharmaceuticals
4.2966 of 5 stars
$11.17
+0.3%
$18.57
+66.3%
+8.8%$950.63MN/A-5.9780

Related Companies and Tools


This page (NASDAQ:AARD) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners